Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
HNC-1058 by Guangzhou Henovcom Bioscience for Systemic Sclerosis (Scleroderma): Likelihood of Approval
HNC-1058 is under clinical development by Guangzhou Henovcom Bioscience and currently in Phase I for Systemic Sclerosis (Scleroderma). According to...
Data Insights
HNC-1058 by Guangzhou Henovcom Bioscience for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
HNC-1058 is under clinical development by Guangzhou Henovcom Bioscience and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to...